Monthly Prescribing Reference21d
STEP UP Trial: Significant Weight Loss Observed With Higher Dose Semaglutide
Study participants were randomly assigned to receive subcutaneous semaglutide 7.2mg, semaglutide 2.4mg, or placebo once weekly; all treatments were in conjunction with lifestyle interventions.
Business Insider21d
Novo Nordisk’s Semaglutide 7.2mg s.c. achieved 21% weight loss in STEP UP trial
The company states: “Novo Nordisk (NVO) announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial investigating ...
WFLA News Channel 824d
Getting back to normal after stopping Semaglutide
TAMPA BAY, Fla. (BLOOM) – If you’ve recently stopped taking semaglutide—commonly known by brand names like Ozempic or Wegovy—you may be wondering how to transition back to normal while ...
pharmaphorum3d
Novo Nordisk will file semaglutide for MASH next year
The topline results from the ESSENCE trial of semaglutide showed that a once-weekly 2.4mg dose of the drug was better than placebo at resolving MASH and improving liver fibrosis, meeting its ...
PMLiVE17d
Novo shares promising results for high-dose semaglutide in late-stage obesity study
The phase 3b STEP UP trial has been comparing the experimental 7.2mg dose of semaglutide to the standard 2.4mg dose of the drug and placebo, all given once weekly in conjunction with lifestyle ...
Yahoo Finance21d
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
In addition, 33.2% of those who received semaglutide 7.2 mg achieved a weight loss of 25% or more after 72 weeks, compared to 16.7% with semaglutide 2.4 mg and 0.0% with placebo.